The funding is being provided by three charities under a program designed to facilitate collaboration between research groups from different institutions.
The Durham, North Carolina-based startup's platform uses an image-based, tissue box-sized tool that cultures cells to capture long-term phenotypic behavior.
An analysis of naturally occurring alleles in the lipoprotein lipase pathway found that they and LDL-C-linked alleles affect disease risk independently.
Researchers profiled the composition and gene content of microbial communities in mouth, gut, and vaginal samples collected from 10 pregnant women.
The company said the NIH funding will enable it to further validate the saliva-based test and prepare it for commercial launch later this year.
By early 2020, the UK company plans to develop a version of its Iona test that uses Illumina's sequencing technology.
The firm has been placing point-of-care systems primarily in the private sector, but may have increased access once it completes WHO prequalification review.
The test detects and quantifies hepatitis C virus RNA and can be performed in approximately one hour.
Fleury will integrate IDbyDNA's Explify platform into its own laboratory workflow and develop a full suite of Explify-based clinical testing.
Based on multiplexed ion beam imaging, the system, which the company plans to launch next year, will compete most directly with Fluidigm's Hyperion platform.
The companies aim to develop microbiome diagnostic assays for colon cancer and other gastrointestinal diseases including irritable bowel syndrome.
Under the terms of the deal, Beijing-based GeneCast has the exclusive right to market Agendia's MammaPrint and BluePrint tests to Chinese customers.
The company's ctDx lung cancer assay identifies a variety of different actionable mutations in the blood of non-small cell lung cancer patients.
Mascots will distribute Lucence's blood-based tests, which detect DNA fragments shed by a tumor, in order to identify cancer-driving mutations.
The deal will join CGI's portfolio of cancer tests and lab services with NovellusDx's technologies for cancer treatment response prediction.
Researchers used fine mapping and other approaches to prioritize proposed coding and non-coding causal variants at rheumatoid arthritis- and type 1 diabetes-linked loci.
The clinical trial matching app, which Roche collaborated on with MolecularMatch, is the latest in a series of features that it will introduce in its tumor board solution.
The international team of researchers uncovered 535 novel risk loci for blood pressure in its analysis, which drew on more than one million people.
Researchers found relevant non-coding mutations in colorectal cancer cell lines by systematically profiling chromosome interactions at promoter fragments.
In a recent study in Blood, the researchers showed that a higher allelic burden after transplantation was associated with higher risk of relapse and mortality.
Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.
The Wall Street Journal looks into the cost of new gene therapies.
An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.
In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.